MedTrace Logo

Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System

NCT04743388 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-04-11

No results posted yet for this study

Summary

Determination of both the degree and duration of the immunity provided after receiving the BNT162b2 vaccine against SARS-Cov-2.

Conditions

Interventions

BIOLOGICAL

BNT162b2

Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies

BIOLOGICAL

Other vaccine against SARS-Cov-2

Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    lead OTHER

Principal Investigators

  • Evangelos Terpos · National and Kapodistrian University of Athens

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2022-08-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04743388 on ClinicalTrials.gov